Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Implementing Geriatric Assessment for Dose Optimization of CDK 4/6-inhibitors in Older Breast Cancer Patients - a Pragmatic Randomized-controlled Trial (IMPORTANT Trial)

Next Previous
Trial Profile

Implementing Geriatric Assessment for Dose Optimization of CDK 4/6-inhibitors in Older Breast Cancer Patients - a Pragmatic Randomized-controlled Trial (IMPORTANT Trial)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Anastrozole (Primary) ; Exemestane (Primary) ; Fulvestrant (Primary) ; Letrozole (Primary) ; Palbociclib (Primary) ; Ribociclib (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use
  • Acronyms IMPORTANT

Most Recent Events

  • 13 Dec 2024 Trial design presented at the 47th Annual San Antonio Breast Cancer Symposium
  • 19 Nov 2024 Planned End Date changed from 1 Apr 2031 to 31 May 2029.
  • 19 Nov 2024 Planned primary completion date changed from 1 Apr 2028 to 31 Oct 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top